Co-clinical Assessment of Tumor Cellularity in Pancreatic Cancer

Purpose: Tumor heterogeneity is a hallmark of pancreatic ductal adenocarcinoma (PDAC). It determines tumor biology including tumor cellularity (i.e., amount of neoplastic cells and arrangement into clusters), which is related to the proliferative capacity and differentiation and the degree of desmoplasia among others. Given the close relation of tumor differentiation with differences in progression and therapy response or, e.g., the recently reported protective role of tumor stroma, we aimed at the noninvasive detection of PDAC groups, relevant for future personalized approaches. We hypothesized that histologic differences in PDAC tissue composition are detectable by the noninvasive diffusion weighted- (DW-) MRI-derived apparent diffusion coefficient (ADC) parameter. Experimental design: PDAC cellularity was quantified histologically and correlated with the ADC parameter and survival in genetically engineered mouse models and human patients. Results: Histologic analysis showed an inverse relationship of tumor cellularity and stroma content. Low tumor cellularity correlated with a significantly prolonged mean survival time (PDAClow = 21.93 months vs. PDACmed = 12.7 months; log-rank P < 0.001; HR = 2.23; CI, 1.41–3.53). Multivariate analysis using the Cox regression method confirmed tumor cellularity as an independent prognostic marker (P = 0.034; HR = 1.73; CI, 1.04–2.89). Tumor cellularity showed a strong negative correlation with the ADC parameter in murine (r = −0.84; CI, −0.90– −0.75) and human (r = −0.79; CI, −0.90 to −0.56) PDAC and high preoperative ADC values correlated with prolonged survival (ADChigh = 41.7 months; ADClow = 14.77 months; log rank, P = 0.040) in PDAC patients. Conclusions: This study identifies high tumor cellularity as a negative prognostic factor in PDAC and supports the ADC parameter for the noninvasive identification of PDAC groups. Clin Cancer Res; 23(6); 1461–70. ©2016 AACR.

[1]  S. Reeder,et al.  Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy , 2011, Journal of magnetic resonance imaging : JMRI.

[2]  F. Bosman,et al.  WHO Classification of Tumours of the Digestive System , 2010 .

[3]  Carlos Cuevas,et al.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[4]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[5]  Umar Mahmood,et al.  Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. , 2015, Cancer cell.

[6]  Derek S. Chan,et al.  Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer , 2012, Gut.

[7]  Yi Wang,et al.  Diffusion‐weighted MR imaging in pancreatic endocrine tumors correlated with histopathologic characteristics , 2011, Journal of magnetic resonance imaging : JMRI.

[8]  Patrick Maisonneuve,et al.  Epidemiology of pancreatic cancer: an overview , 2009, Nature Reviews Gastroenterology &Hepatology.

[9]  Lawrence Tanenbaum,et al.  Diffusion‐weighted imaging outside the brain: Consensus statement from an ISMRM‐sponsored workshop , 2016, Journal of magnetic resonance imaging : JMRI.

[10]  Mauro Ferrari,et al.  Transport properties of pancreatic cancer describe gemcitabine delivery and response. , 2014, The Journal of clinical investigation.

[11]  Bram Stieltjes,et al.  Fibrosis and Pancreatic Lesions: Counterintuitive Behavior of the Diffusion Imaging–Derived Structural Diffusion Coefficient D , 2013, Investigative radiology.

[12]  Jens T Siveke,et al.  EGF receptor is required for KRAS-induced pancreatic tumorigenesis. , 2012, Cancer cell.

[13]  R. Pozzi Mucelli,et al.  Perfusion CT can predict tumoral grading of pancreatic adenocarcinoma. , 2013, European journal of radiology.

[14]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration , 2012, BMC Medicine.

[15]  E. Collisson,et al.  Subtype-Specific MEK-PI3 Kinase Feedback as a Therapeutic Target in Pancreatic Adenocarcinoma , 2013, Molecular Cancer Therapeutics.

[16]  Sunil J Rao,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2003 .

[17]  R. Schmid,et al.  Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. , 2007, Cancer cell.

[18]  M. Miyazaki,et al.  Prognostic relevance of apparent diffusion coefficient obtained by diffusion‐weighted MRI in pancreatic cancer , 2015, Journal of magnetic resonance imaging : JMRI.

[19]  Achim Zeileis,et al.  Generalized Maximally Selected Statistics , 2008, Biometrics.

[20]  R. Bammer Basic principles of diffusion-weighted imaging. , 2003, European journal of radiology.

[21]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[22]  R. Weinberg,et al.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.

[23]  Kurt Hornik,et al.  Implementing a Class of Permutation Tests: The coin Package , 2008 .

[24]  Michael A. Choti,et al.  Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets , 2015, Nature Communications.

[25]  L. Strauss,et al.  Tumor Aggressiveness and Patient Outcome in Cancer of the Pancreas Assessed by Dynamic 18F-FDG PET/CT , 2013, The Journal of Nuclear Medicine.

[26]  J. Willmann,et al.  Stromal response to Hedgehog signaling restrains pancreatic cancer progression , 2014, Proceedings of the National Academy of Sciences.

[27]  A. Rosenkrantz,et al.  Pancreatic cancer: lack of association between apparent diffusion coefficient values and adverse pathological features. , 2013, Clinical radiology.

[28]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[29]  J. Kench,et al.  Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.

[30]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[31]  D. Collins,et al.  Diffusion-weighted MRI in the body: applications and challenges in oncology. , 2007, AJR. American journal of roentgenology.

[32]  D. Le Bihan,et al.  Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. , 1988, Radiology.

[33]  S. Reeder,et al.  Fat confounds the observed apparent diffusion coefficient in patients with hepatic steatosis , 2013, Magnetic resonance in medicine.

[34]  S. Baylin,et al.  Absence of E-Cadherin Expression Distinguishes Noncohesive from Cohesive Pancreatic Cancer , 2008, Clinical Cancer Research.

[35]  P. Spellman,et al.  Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy , 2011, Nature Medicine.

[36]  E. Furth,et al.  Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. , 2006, Cancer research.

[37]  Anneleen Daemen,et al.  Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors , 2015, Proceedings of the National Academy of Sciences.

[38]  H. Uematsu,et al.  Apparent diffusion coefficient in pancreatic cancer: Characterization and histopathological correlations , 2008, Journal of magnetic resonance imaging : JMRI.